EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Rhea-AI Summary

EyePoint Pharmaceuticals, Inc. (EYPT) announced that George Elston, EVP and CFO, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Feb 7, 2024. The webcast can be accessed via the Company website. This event aims to improve the lives of patients with serious retinal diseases.

Positive

• Participation in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference showcases the company's commitment to developing and commercializing therapeutics for serious retinal diseases.
• The live webcast and archived replay of the fireside chat provide accessibility for investors and stakeholders.
• The event aims to improve the lives of patients with serious retinal diseases, aligning with the company's mission and goals.

Negative

• None.

WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that George Elston, Executive Vice President and Chief Financial Officer of EyePoint Pharmaceuticals, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 12:30 p.m. ET.

A live webcast and subsequent archived replay of the fireside chat may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, EYP-1901, is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E™. Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, f/k/a AKB-9778, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert^® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

Investors:
Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com

Media Contact
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

When is the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference?

The conference is on February 7, 2024.

Who will participate in the fireside chat at the conference?

George Elston, EVP and CFO of EyePoint Pharmaceuticals, Inc.

What is the purpose of the fireside chat?

To discuss the company's commitment to developing and commercializing therapeutics for serious retinal diseases.

Where can the webcast be accessed?

The webcast can be accessed via the Investors section of the Company website at www.eyepointpharma.com.

How long will the replay of the fireside chat be available?

The replay will be available for 90 days after the event.